{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:36Z","timestamp":1789469136794,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed CAR T-cell therapy approved for relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) based on the pilot study ZUMA-2. Since then, several US and European real-world studies have demonstrated comparable efficacy outcomes. However, these reports have also suggested potentially higher rates of acute toxicities, particularly immune effector cell\u2013associated neurotoxicity syndrome (ICANS), raising concerns regarding its use, especially in vulnerable populations. At Singapore General Hospital, five patients (median age 75 years) received brexu-cel from April 2025 to Dec 2025 for R\/R MCL. Historical cohort MCL patients received allogeneic haematopoietic stem cell transplantation (allo-HSCT) were extracted and compared. For brexu-cel cohort, the overall response rate (ORR) was 100%, with a complete response rate (CRR) of 80%. Cytokine release syndrome (CRS) occurred in 80% of patients, with no grade 3 events, and only one patient developed grade 1 ICANS (20%). These efficacy and safety outcomes compare favourably with historical cohorts of patients who underwent allo-HSCT locally (total 6 patients, 2 relapsed, 2 NRM), despite potentially higher-risk features and less controlled disease at baseline. Efficacy and toxicity of both clinical trial and real-world CAR-T studies for R\/R MCL were summarized. To our knowledge, this represents the first real-world report from Asia on brexu-cel in R\/R MCL, supporting its use in this region, where published data have thus far predominantly originated from the United States and Europe.<\/jats:p>","DOI":"10.1007\/s00277-026-07126-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:58:22Z","timestamp":1781881102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"105","author":[{"given":"Lawrence Cheng Kiat","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Yuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yeu","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Li Mei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aloysius Yew Leng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Wei Inng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"16","key":"7126_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K (2018) Update on mantle cell lymphoma. Blood 132(16):1647\u20131656. https:\/\/doi.org\/10.1182\/blood-2018-03-791392","journal-title":"Blood"},{"issue":"6","key":"7126_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL et al (2019) Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J 9(6):50","journal-title":"Blood Cancer J"},{"issue":"4","key":"7126_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2023","unstructured":"Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K et al (2023) Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol 202(4):749\u2013759. https:\/\/doi.org\/10.1111\/bjh.18519","journal-title":"Br J Haematol"},{"issue":"4","key":"7126_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS et al (2017) Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a real world study. Hematol Oncol 35(4):528\u2013535. https:\/\/doi.org\/10.1002\/hon.2380","journal-title":"Hematol Oncol"},{"issue":"2","key":"7126_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2014.223","volume":"29","author":"S Robinson","year":"2015","unstructured":"Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M et al (2015) European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 29(2):464\u2013473","journal-title":"Leukemia"},{"issue":"14","key":"7126_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2020) KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382(14):1331\u20131342","journal-title":"N Engl J Med"},{"issue":"3","key":"7126_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2023) Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 41(3):555\u2013567","journal-title":"J Clin Oncol"},{"issue":"20","key":"7126_CR8","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","volume":"9","author":"N Ahmed","year":"2025","unstructured":"Ahmed N, Thiruvengadam SK, Hamadani M, Hu ZH, Grover N, Shadman M et al (2025) Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv 9(20):5382\u20135396","journal-title":"Blood Adv"},{"issue":"6","key":"7126_CR9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","volume":"8","author":"EH Nie","year":"2024","unstructured":"Nie EH, Su YJ, Baird JH, Agarwal N, Bharadwaj S, Weng WK et al (2024) Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Adv 8(6):1474\u20131486","journal-title":"Blood Adv"},{"issue":"12","key":"7126_CR10","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F et al (2022) Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 6(12):3606\u20133610","journal-title":"Blood Adv"},{"issue":"10","key":"7126_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV et al (2024) Lisocabtagene Maraleucel in Relapsed\/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol 42(10):1146\u20131157. https:\/\/doi.org\/10.1200\/JCO.23.02214","journal-title":"J Clin Oncol"},{"issue":"4","key":"7126_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/bloodadvances.2024015763","volume":"10","author":"Y Xie","year":"2026","unstructured":"Xie Y, Zhou KS, Li LF, Liang AB, Mei H, Zou DH et al (2026) Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed\/refractory mantle cell lymphoma in Chinese adults. Blood Adv 10(4):1134\u20131144","journal-title":"Blood Adv"},{"issue":"19","key":"7126_CR13","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019\u20135032","journal-title":"Blood"},{"issue":"20","key":"7126_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"35","key":"7126_CR15","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M et al (2021) Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol 39(35):3978\u20133992","journal-title":"J Clin Oncol"},{"issue":"3","key":"7126_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1600-0609.2008.01096.x","volume":"81","author":"M Caira","year":"2008","unstructured":"Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT et al (2008) Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 81(3):242\u2013243","journal-title":"Eur J Haematol"},{"key":"7126_CR17","doi-asserted-by":"crossref","unstructured":"Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci et al (2014) Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses. 2014;57(6):342\u2009\u2013\u200950","DOI":"10.1111\/myc.12161"},{"issue":"1","key":"7126_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.47102\/annals-acadmedsg.2024178","volume":"54","author":"WSJ Loke","year":"2024","unstructured":"Loke WSJ, Catapia JR, Low CL, Lim F, Quek J, Than H et al (2024) Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse\/refractory lymphoma: A 20-year Singapore experience. Ann Acad Med Singap 54(1):5\u201316","journal-title":"Ann Acad Med Singap"},{"issue":"10","key":"7126_CR19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C et al (2019) European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl 54(10):1525\u20131552","journal-title":"Bone Marrow Transpl"},{"key":"7126_CR20","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol, 32(27), 3059\u20133067","DOI":"10.1200\/JCO.2013.54.8800"},{"issue":"4","key":"7126_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"7126_CR22","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL et al (2023) Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 41(14):2594\u20132606","journal-title":"J Clin Oncol"},{"issue":"6","key":"7126_CR23","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B et al (2024) Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis. Hemasphere 8(6):e87","journal-title":"Hemasphere"},{"issue":"11","key":"7126_CR24","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.3324\/haematol.2023.284786","volume":"109","author":"C Herbaux","year":"2024","unstructured":"Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A et al (2024) Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica 109(11):3745\u20133750","journal-title":"Haematologica"},{"key":"7126_CR25","doi-asserted-by":"publisher","unstructured":"Puckrin R, Sapon-Cousineau V, Peters A, Owen C, Shafey M (2025) Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed\/refractory mantle cell lymphoma. Bone Marrow Transplant. Dec 26. https:\/\/doi.org\/10.1038\/s41409-025-02786-w. Epub ahead of print. PMID: 41454023","DOI":"10.1038\/s41409-025-02786-w"},{"key":"7126_CR26","doi-asserted-by":"crossref","unstructured":"Simon L, Vucinic V, Rejeski K, Schubert ML, Aydilek E, Wagner-Drouet EM et al (2026) Results of brexucabtagene-autoleucel for patients with relapsed\/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland. Bone Marrow Transpl. Jan 16","DOI":"10.1038\/s41409-025-02789-7"},{"key":"7126_CR27","doi-asserted-by":"crossref","unstructured":"Santoro N, Mooyaart JE, Novak U, Protheroe R, Ayuk FA, Dreger P et al (2026) OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R\/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT, Blood Advances. ISSN 2473\u20139529","DOI":"10.1182\/bloodadvances.2025019367"},{"issue":"22","key":"7126_CR28","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","volume":"30","author":"H Hubbeling","year":"2024","unstructured":"Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G et al (2024) Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma. Clin Cancer Res 30(22):5083\u20135093","journal-title":"Clin Cancer Res"},{"key":"7126_CR29","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly MA, Wilson W, Maybury B, Kuhnl A, Roddie C, Uttenthal B et al (2026) Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival. Br J Haematol. Mar 8","DOI":"10.1111\/bjh.70357"},{"issue":"9","key":"7126_CR30","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS et al (2024) A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 30(9):2667\u20132678","journal-title":"Nat Med"},{"issue":"21","key":"7126_CR31","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","volume":"7","author":"J Lemoine","year":"2023","unstructured":"Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, Di Blasi R et al (2023) Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv 7(21):6589\u20136598","journal-title":"Blood Adv"},{"issue":"8","key":"7126_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO-25-02087","volume":"44","author":"RG Faramand","year":"2026","unstructured":"Faramand RG, Xie Z, Jain MD (2026) Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. J Clin Oncol 44(8):698\u2013708","journal-title":"J Clin Oncol"},{"issue":"5","key":"7126_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11864-025-01316-6","volume":"26","author":"LCK Ng","year":"2025","unstructured":"Ng LCK, Ng RQM, DiTursi J, Loh KP (2025) Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies. Curr Treat Options Oncol 26(5):348\u2013359","journal-title":"Curr Treat Options Oncol"},{"key":"7126_CR34","doi-asserted-by":"crossref","unstructured":"Yoon DH, Cho H, Chan JY, Kim D, Kato K, Kang KW et al (2025) Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study. [abstract] Blood, Volume 146, Supplement 1, Page 2778, ISSN 0006-4971","DOI":"10.1182\/blood-2025-2778"},{"issue":"12","key":"7126_CR35","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH et al (2023) Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis. Cancer Med 12(12):13204\u201313216","journal-title":"Cancer Med"},{"issue":"5","key":"7126_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J et al (2018) Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transpl 53(5):617\u2013624","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"7126_CR37","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","volume":"16","author":"G Cook","year":"2010","unstructured":"Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al (2010) Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT). Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl 16(10):1419\u20131427","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"7126_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2643-3230.BCD-24-0178","volume":"6","author":"N Liebers","year":"2025","unstructured":"Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann BN et al (2025) Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Blood Cancer Discov 6(3):182\u2013190","journal-title":"Blood Cancer Discov"},{"key":"7126_CR39","doi-asserted-by":"crossref","unstructured":"Ge AY, Feldman WB, Kaiser MF, Rejeski K, Iacoboni G, Narula G et al (2026) Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20. Blood. 16:blood2025030872","DOI":"10.1182\/blood.2025030872"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07126-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07126-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:43:00Z","timestamp":1789465380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07126-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7126"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07126-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9688623\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study was done under the approval of Singhealth transplant registry (CRIB 2015\u20132419) and National University Hospital transplant registry (CIRB 2010\/00431).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MLMP: Travel support by Kite\/ GiLEAD.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"402"}}